NTT-COMM/CA-RAGINGWIRE
RagingWire Data Centers, Inc., the premier data center provider in North America and part of the global data center platform of NTT Communications (NTT Com), the information and communications technology (ICT) solutions and international communications business within the NTT Group (TOKYO:9432), today announced that it has purchased land and has begun developing a new world-class, 16 megawatt data center “California Silicon Valley 1 (SV1) Data Center” in Santa Clara, the heart of the tech capital of the world – Silicon Valley.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005270/en/
Planned for availability in July 2020, RagingWire’s SV1 marks the company’s entry into the Silicon Valley region, which is widely known as the No. 2 data center market in the United States behind Ashburn, Va., in terms of commissioned power. RagingWire also has significant data center campuses in Ashburn, Va., Dallas, Texas, and Sacramento, Calif., and has purchased land in Chicago, Ill. for a new data center development.
“This is an important milestone in our company’s history,” said RagingWire President and CEO Doug Adams. “With the addition of Silicon Valley to our portfolio, we now have data center options in the top three data center markets – Ashburn, Silicon Valley, and Dallas – plus land for build-to-suit data centers in Chicago, the #4 U.S. data center market, and we are part of the global data center platform of NTT Com in over 20 countries and regions.”
Highly coveted by major IT firms and public cloud providers, new data center space in Santa Clara is also extremely rare. The vacancy rate is less than 8 percent among the more than 30 data centers operating within an area of 3.5 square miles in Santa Clara. To address this demand, RagingWire is now accepting first customer commitments and leases for SV1.
“The supply of wholesale data center space in Silicon Valley is constrained,” said Kelly Morgan, Vice President at 451 Research. “Many providers no longer have room to expand, and it is difficult to find suitable land with the necessary power and environmental characteristics needed to obtain permits. New data center space in Silicon Valley, particularly Santa Clara, is typically leased before it is available and commissioned.”
With SV1, RagingWire is delivering data center space designed for hyperscale cloud companies and large enterprises with the capability for them to customize their data vaults. The 160,000 square-foot, four-story facility is being built on a 3.3 acre site, with 64,000 square feet of data floor space and 16 megawatts of scalable, critical IT power. SV1 is fed by Silicon Valley Power, which has rates that are 25 to 40 percent lower than other Bay Area power companies, is rated in the top 5% in the U.S. for reliability, and has been nationally honored for its renewable energy programs.
A compelling structural attribute of SV1 is its seismic stability system that reduces shocks from earthquakes. This state-of-the-art design utilizes a base isolation system that incorporates a combination of subterranean pendulum isolation and viscous dampers to protect the building and everything inside it.
The same base isolation system was used by RagingWire’s parent company, NTT Com, to save its data centers in Tokyo, Japan from damage during a 9.1-magnitude earthquake and tsunami in 2011. That event became the costliest natural disaster in history, causing approximately $235 billion of damage, but the NTT Com’s data centers protected with this system were unharmed.
SV1 is designed for flexibility and scale, with options for dedicated electrical and mechanical infrastructure. The facility features a rich ecosystem of connectivity options to major carriers, cloud providers, content networks, and other data centers.
For exceptional security, SV1 uses a building-within-a-building design, biometric identification systems, intelligent high-definition video cameras that analyze suspicious behavior, anti-tailgate mantraps, an anti-climb perimeter fence, and a security gate that can stop a 15,000-pound truck traveling at 30 mph.
Conveniently located in Santa Clara, less than four miles from San Jose International Airport, SV1 is less than two miles from the Bayshore Freeway, and less than one mile from the San Tomas Expressway.
About RagingWire Data Centers
RagingWire Data Centers designs, builds, and operates mission critical data centers that deliver 100% availability, high-density power, flexible configurations, carrier neutral connectivity, and superior customer service. The company has 245MW of critical IT load spread across 2 million square feet of data center infrastructure in Ashburn, Virginia; Dallas, Texas; and Sacramento and Silicon Valley in Northern California with significant growth plans in these locations and other top North American data center markets. As part of the NTT Communications group, RagingWire is one of the largest wholesale data center providers in the world with a global network of data centers in over 20 countries and regions operated by NTT Communications under the Nexcenter™ brand and one of the most financially strong companies in the data center industry. For more information visit www.ragingwire.com .
About NTT Communications
NTT Communications solves the world’s technology challenges by helping
enterprises overcome complexity and risk in their ICT environments with
managed IT infrastructure solutions. These solutions are backed by our
worldwide infrastructure, including industry leading, global tier-1
public and private networks reaching over 190 countries/regions, and
more than 400,000m2
of the world’s most advanced data center
facilities. Our global professional services teams provide consultation
and architecture for the resiliency and security required for your
business success, and our scale and global capabilities are unsurpassed.
Combined with NTT Data, NTT Security, NTT DOCOMO and Dimension Data, we
are NTT Group.
www.ntt.com
| Twitter@NTT
Com
| Facebook@NTT
Com
| LinkedIn@NTT
Com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005270/en/
Contact:
Mr. Hiroshi Seo Cloud Services NTT Communications Mail: wg-cl@ntt.com
RagingWire Data Centers Evan Bass +1-703-840-7737 ebass@ragingwire.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom